Symbion is helping to educate pharmacy about the impacts of codeine changes
The wholesaler is conducting a series of forums around the country to help manage the transition of low-dose codeine to Prescription Only on 1 February 2018.
National manager of Symbion businesses Pharmacy Choice and healthSAVE Luke McKinnon saysd the forums outlining the codeine up-scheduling impact are an important vehicle to assist pharmacy in dealing with these challenges.
“Front-line pharmacy plays a critical role in educating consumers about alternative medication solutions where they benefit the patient’s health outcome,” he says.
“These forums are a significant opportunity to ensure pharmacists handing out the script continue to deliver professional service at the medicine counter.
“We are working closely with pharmacy to manage the transition in stock levels – introducing new products, and phasing out S2 and S3 products – as well as helping them understand the impacts on their business and how they can continue to deliver high levels of service to their customers come February next year.”
Currently, S3 codeine sales contribute an average of 48% of total gross profit dollars (GP$) in the pain category, highlighting the significant financial challenges the changes will bring.
“We are actively encouraging all our Pharmacy Choice and healthSAVE members to do their numbers by utilising our Store IQ Codeine Impact report. This will provide pharmacy with the visibility on codeine sales and profit impacts they need to successfully manage the transition,” Mr McKinnon says.
“By being a valued customer of Symbion, our customers can access vital information, insight and advice into issues around codeine up-scheduling. These forums are just one way in which we are helping pharmacy to work through the transition.”
The next Symbion forum will take place in Canberra on Tuesday 6th September.